No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
FDA Grants Priority Review of AbbVie’s sBLA for EPKINLY® (epcoritamab SC)
On 27 February 2024, AbbVie announced that the U.S. Food and Drug Administration (FDA) granted priority review of its supplemental Biologics License Application for EPKINLY® (epcoritamab) for the treatment of Adult Relapsed or Refractory Follicular Lymphoma (R/R FL). ...